Views & Analysis Considerations for Mobile Health Technology Developers: Part... In Part 1 of this series, general wellness devices and mobile me
Views & Analysis Considerations for Mobile Health Technology Developers: Part... In Part 1 of this series, general wellness devices and mobile medical applications (MMAs) will be considered. Part 2 of this series will be devoted to clinical decision support (C
Views & Analysis The real conspiracy in the pharma industry Paul Tunnah on how pharma industry workers can negatively affect patients without even realising it.
Partner Content Partner Content PLIVA explores impact of EU Guidelines on evaluation of modi... PLIVA explores EU Guidelines for modified release drugs
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.